Eugenia Gianos1, Antoinette Schoenthaler2, Michael Mushailov3, Edward A Fisher4, Jeffrey S Berger4. 1. Department of Medicine, Division of Cardiology, Center for the Prevention of Cardiovascular Disease, New York University School of Medicine, New York, NY. Electronic address: Eugenia.Gianos@nyumc.org. 2. Department of Population Health, Center for Healthful Behavioral Change, New York University School of Medicine, New York, NY. 3. Department of Medicine, Division of Cardiology, Center for the Prevention of Cardiovascular Disease, New York University School of Medicine, New York, NY. 4. Department of Medicine, Division of Cardiology, Center for the Prevention of Cardiovascular Disease, New York University School of Medicine, New York, NY; Marc and Ruti Bell Program in Vascular Biology, New York University School of Medicine, New York, NY.
Abstract
BACKGROUND: Patients undergoing cardiovascular procedures remain at increased risk for myocardial infarction, stroke, and cardiovascular death. Risk factor control in this patient population remains suboptimal and would likely benefit from strategies targeting education, lifestyle, and healthy behaviors. DESIGN: The IMPACT trial is a 400-subject prospective randomized trial designed to compare different cardiovascular prevention strategies in subjects following a cardiovascular intervention. The trial began enrollment in the Spring of 2012 and is randomizing subjects in a 1:1:1 manner to usual care, a one-time cardiovascular prevention consult, or a one-time cardiovascular prevention consult plus behavioral intervention program (telephone-based motivational interviewing and tailored text messages) over a 6-month period. The primary end point is non-high-density lipoprotein cholesterol. Secondary end points include other plasma lipid values, metabolic risk, smoking cessation, physical activity, dietary intake, medication use and adherence, and quality of life. CONCLUSIONS: The IMPACT trial provides data on different management strategies for risk factor optimization in subjects following cardiovascular procedures. The results will provide a platform for the continued development of novel multidisciplinary interventions in this high-risk population.
RCT Entities:
BACKGROUND:Patients undergoing cardiovascular procedures remain at increased risk for myocardial infarction, stroke, and cardiovascular death. Risk factor control in this patient population remains suboptimal and would likely benefit from strategies targeting education, lifestyle, and healthy behaviors. DESIGN: The IMPACT trial is a 400-subject prospective randomized trial designed to compare different cardiovascular prevention strategies in subjects following a cardiovascular intervention. The trial began enrollment in the Spring of 2012 and is randomizing subjects in a 1:1:1 manner to usual care, a one-time cardiovascular prevention consult, or a one-time cardiovascular prevention consult plus behavioral intervention program (telephone-based motivational interviewing and tailored text messages) over a 6-month period. The primary end point is non-high-density lipoprotein cholesterol. Secondary end points include other plasma lipid values, metabolic risk, smoking cessation, physical activity, dietary intake, medication use and adherence, and quality of life. CONCLUSIONS: The IMPACT trial provides data on different management strategies for risk factor optimization in subjects following cardiovascular procedures. The results will provide a platform for the continued development of novel multidisciplinary interventions in this high-risk population.
Authors: Alma J Adler; Nicole Martin; Javier Mariani; Carlos D Tajer; Onikepe O Owolabi; Caroline Free; Norma C Serrano; Juan P Casas; Pablo Perel Journal: Cochrane Database Syst Rev Date: 2017-04-29
Authors: Eugenia Gianos; Antoinette Schoenthaler; Yu Guo; Judy Zhong; Howard Weintraub; Arthur Schwartzbard; James Underberg; Michael Schloss; Jonathan D Newman; Sean Heffron; Edward A Fisher; Jeffrey S Berger Journal: Am Heart J Date: 2018-01-09 Impact factor: 4.749